AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10080464 — intervention group
Group type: COMPARATOR
Intervention: No CK elevation
Number of subjects: 2099
Study 10080464 — intervention group
Group type: COMPARATOR
Intervention: CK elevation to >3 times normal
Number of subjects: 2099
Study 10080464 — intervention group
Group type: COMPARATOR
Intervention: CK elevation to >10 times normal
Number of subjects: 2099
Study 7484023 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% desflurane
Number of subjects: 75
Study 7484023 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% desflurane
Number of subjects: 75
Study 7484023 — intervention group
Group type: COMPARATOR
Intervention: 0.6% enflurane
Number of subjects: 75
Study 7484023 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% N2O and O2
Number of subjects: 75
Study 7484023 — intervention group
Group type: EXPERIMENTAL
Intervention: butorphanol tartrate
Number of subjects: 75
Study 2149281 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene (oral doses of 10-480 mg per day for one or five days)
Number of subjects: 27
Study 2149281 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene
Number of subjects: 27
Study 7369562 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis catheter
Number of subjects: 100
Study 7369562 — intervention group
Group type: COMPARATOR
Intervention: Intracatheter
Number of subjects: 100
Study 30058726 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily oral 100 mg KH176 for 28 days
Number of subjects: 18
Study 30058726 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 18
Study 28134225 — intervention group
Group type: EXPERIMENTAL
Intervention: LABA (long-acting beta-agonist) such as indacaterol, vilanterol, or olodaterol used once a day.
Number of subjects: 0
Study 28134225 — intervention group
Group type: EXPERIMENTAL
Intervention: LAMA (long-acting muscarinic antagonist) such as tiotropium, glycopyrronium, aclidinium, or umeclidinium.
Number of subjects: 0
Study 28134225 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined preparations of LAMA-LABA.
Number of subjects: 0
Study 28134225 — intervention group
Group type: EXPERIMENTAL
Intervention: MABA (muscarinic antagonist and β2 agonist).
Number of subjects: 0
Study 26489713 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal extraction
Number of subjects: 27
Study 26489713 — intervention group
Group type: COMPARATOR
Intervention: Conventional extraction
Number of subjects: 27
Study 23636925 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 163
Study 23636925 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 163
Study 20939799 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide intravitreal implant (Retisert)
Number of subjects: 0
Study 20939799 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide intravitreal implant (Iluvien)
Number of subjects: 0
Study 20939799 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination photocoagulation and pharmacotherapy
Number of subjects: 0
Study 19640669 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol and 4-hydroxy propranolol assay using solid phase extraction and liquid chromatography/electrospray tandem mass spectrometry
Number of subjects: 0
Study 17595894 — intervention group
Group type: EXPERIMENTAL
Intervention: Digox 0.25 mg tablet from Pharlab Ind. Ltd., Brazil
Number of subjects: 30
Study 17595894 — intervention group
Group type: COMPARATOR
Intervention: Digoxin 0.25 mg tablet from Laboratório Glaxo SmithKline, Brazil
Number of subjects: 30
Study 15533493 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg
Number of subjects: 22
Study 15533493 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 20 mg
Number of subjects: 22
Study 15533493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 14740593 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled hyperventilation (hypocapnia)
Number of subjects: 0
Study 14740593 — intervention group
Group type: COMPARATOR
Intervention: Normocapnic group
Number of subjects: 0
Study 9850831 — intervention group
Group type: EXPERIMENTAL
Intervention: Social phobia diagnosis
Number of subjects: 1035
Study 9850831 — intervention group
Group type: EXPERIMENTAL
Intervention: Social fears
Number of subjects: 1035
Study 9850831 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-occurring disorders
Number of subjects: 1035
Study 9850831 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial impairment
Number of subjects: 1035
Study 9850831 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional help
Number of subjects: 1035
Study 7851519 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) applied 80 ms before or 60 ms after the go-signal overlying the supplementary motor area (SMA)
Number of subjects: 8
Study 7851519 — intervention group
Group type: COMPARATOR
Intervention: Different stimulation intervals (160 ms and 120 ms before the go-signal; 100 ms, 140 ms or 240 ms after the go-signal) and inappropriate coil positioning (over the occipital cortex)
Number of subjects: 8
Study 7851519 — intervention group
Group type: COMPARATOR
Intervention: Low stimulator output
Number of subjects: 8
Study 2528440 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac (600 mg/day)
Number of subjects: 210
Study 2528440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 363232 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1 g daily
Number of subjects: 60
Study 363232 — intervention group
Group type: COMPARATOR
Intervention: Carbenoxolone (for patients under 60)
Number of subjects: 60
Study 363232 — intervention group
Group type: COMPARATOR
Intervention: Caved-(S) (for patients over 60)
Number of subjects: 60
Study 363232 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up of healed ulcers
Number of subjects: 60
Study 31730814 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-viral therapy
Number of subjects: 335
Study 31730814 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in HBsAg
Number of subjects: 335
Study 31730814 — intervention group
Group type: COMPARATOR
Intervention: HBcrAg conversion rates
Number of subjects: 335
Study 28517974 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA + aspirin therapy (2 g DHA + 81 mg aspirin daily)
Number of subjects: 55
Study 28517974 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo capsules)
Number of subjects: 55
Study 25867448 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-system therapy (SST)
Number of subjects: 49
Study 25867448 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 49
Study 25867448 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (CBT and SST)
Number of subjects: 49
Study 22663759 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone consultation for 3 months
Number of subjects: 80
Study 22663759 — intervention group
Group type: COMPARATOR
Intervention: Attendance education during monthly visits at the center
Number of subjects: 80
Study 20523042 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (Xience v/Promus)
Number of subjects: 2678
Study 20523042 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (Cypher Select+)
Number of subjects: 2678
Study 18451229 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 106
Study 18451229 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 106
Study 15347632 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance-trained men
Number of subjects: 14
Study 15347632 — intervention group
Group type: COMPARATOR
Intervention: Untrained men
Number of subjects: 14
Study 12686509 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal acid infusion (0.1 N HCl)
Number of subjects: 10
Study 12686509 — intervention group
Group type: COMPARATOR
Intervention: Water infusion (control)
Number of subjects: 10
Study 10553182 — intervention group
Group type: EXPERIMENTAL
Intervention: Music
Number of subjects: 156
Study 10553182 — intervention group
Group type: EXPERIMENTAL
Intervention: White noise
Number of subjects: 156
Study 10553182 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 156
Study 8678498 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU (500-750 mg/body) and LV (30 mg/body) for 5 days
Number of subjects: 21
Study 8678498 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU (500-750 mg/body) and LV (30 mg/body) plus cisplatin (10 mg/body)
Number of subjects: 21
Study 8678498 — intervention group
Group type: COMPARATOR
Intervention: 5-FU/LV
Number of subjects: 21
Study 8678498 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU/LV/CDDP
Number of subjects: 21
Study 1872778 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid
Number of subjects: 45
Study 1872778 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 45
Study 1872778 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose monophasic combined oral contraceptive
Number of subjects: 45
Study 1872778 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose danazol
Number of subjects: 45
Study 6681365 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnarizine
Number of subjects: 112
Study 6681365 — intervention group
Group type: COMPARATOR
Intervention: Aviomarin and placebo
Number of subjects: 112
Study 29117757 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone
Number of subjects: 372
Study 29117757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study 30092948 — intervention group
Group type: EXPERIMENTAL
Intervention: ADMA tertile groups
Number of subjects: 5004
Study 30092948 — intervention group
Group type: EXPERIMENTAL
Intervention: SDMA tertile groups
Number of subjects: 5004
Study 30092948 — intervention group
Group type: EXPERIMENTAL
Intervention: ADMA and SDMA incorporation into CHA2DS2-VASc or HAS-BLED predictive models
Number of subjects: 5004
Study 26879246 — intervention group
Group type: EXPERIMENTAL
Intervention: Strip shaving
Number of subjects: 200
Study 26879246 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional shaving
Number of subjects: 200
Study 26879246 — intervention group
Group type: COMPARATOR
Intervention: Both groups (strip shaving and regional shaving)
Number of subjects: 200
Study 25140396 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg/day (R10)
Number of subjects: 12
Study 25140396 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg/day (R40)
Number of subjects: 12
Study 25140396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 22189289 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin administration
Number of subjects: 42
Study 22189289 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 42
Study 19948517 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy
Number of subjects: 1015
Study 19948517 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 1015
Study 17661764 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (Sandostatin LAR 20 mg i.m.)
Number of subjects: 46
Study 17661764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 17974149 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CYP)
Number of subjects: 22
Study 17974149 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA)
Number of subjects: 22
Study 17974149 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA)
Number of subjects: 22
Study 15679243 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive radiotherapy
Number of subjects: 0
Study 15679243 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant cisplatin-based chemotherapy with radiotherapy
Number of subjects: 0
Study 15679243 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (cisplatin-5FU) followed by local treatment
Number of subjects: 0
Study 15679243 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial surgery or radiotherapy
Number of subjects: 0
Study 15679243 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 10737578 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection in the internal anal sphincter on each side of the posterior midline (group I)
Number of subjects: 50
Study 10737578 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection in the internal anal sphincter on each side of the anterior midline (group II)
Number of subjects: 50
Study 8725483 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral resection of the prostate (surgery)
Number of subjects: 53
Study 8725483 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment (medication)
Number of subjects: 53
Study 1328978 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen-progestin hormone replacement therapy
Number of subjects: 84
Study 1328978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 1328978 — intervention group
Group type: COMPARATOR
Intervention: Women who had never taken hormone replacement therapy
Number of subjects: 84
Study 1328978 — intervention group
Group type: EXPERIMENTAL
Intervention: Women who had ever taken hormone replacement therapy
Number of subjects: 84
Study 3894171 — intervention group
Group type: EXPERIMENTAL
Intervention: prednisolone metasulphobenzoate enema
Number of subjects: 40
Study 3894171 — intervention group
Group type: COMPARATOR
Intervention: prednisolone‐21‐phosphate enema
Number of subjects: 40
Study 31564529 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-testing
Number of subjects: 182119
Study 31564529 — intervention group
Group type: EXPERIMENTAL
Intervention: HR-HPV screening
Number of subjects: 182119
Study 31564529 — intervention group
Group type: COMPARATOR
Intervention: Cytology screening
Number of subjects: 182119
Study 30640505 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational interview (BMI)
Number of subjects: 167
Study 30640505 — intervention group
Group type: COMPARATOR
Intervention: Attention-matched control (relaxation training [REL])
Number of subjects: 167
Study 28606669 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotary Mtwo instruments (VDW, Munich, Germany) with 8 files
Number of subjects: 30
Study 28606669 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciproc system (VDW) with a single file
Number of subjects: 30
Study 28606669 — intervention group
Group type: EXPERIMENTAL
Intervention: Genius hybrid instruments with 3 files (1 rotary and 2 reciprocating files)
Number of subjects: 30
Study 26376093 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (15-20 hours of training/week + restrictive diet)
Number of subjects: 90
Study 26376093 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive resistance, intensive endurance, moderate mixed exercise modalities
Number of subjects: 90
Study 26376093 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 90
Study 26376093 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive exercise program
Number of subjects: 90
Study 23650408 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine plus rituximab (BR)
Number of subjects: 63
Study 21159397 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 25
Study 21159397 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 25
Study 21159397 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-comfort-scores
Number of subjects: 25
Study 21159397 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment times
Number of subjects: 25
Study 19635587 — intervention group
Group type: COMPARATOR
Intervention: Basic office evaluation (BOE) prior to SUI surgery (No UDS arm)
Number of subjects: 0
Study 19635587 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic office evaluation and urodynamic studies (UDS) prior to SUI surgery (UDS arm)
Number of subjects: 0
Study 19635587 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative UDS
Number of subjects: 0
Study 19635587 — intervention group
Group type: COMPARATOR
Intervention: No UDS
Number of subjects: 0
Study 17533068 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including instructional materials, cues and aids, a video, brief counseling session, follow-up phone call, and tailored feedback letters.
Number of subjects: 1356
Study 17533068 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Number of subjects: 1356
Study 17533068 — intervention group
Group type: COMPARATOR
Intervention: Control intervention focused on diet
Number of subjects: 1356
Study 15730803 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized Three Stages' Rehabilitation
Number of subjects: 52
Study 15730803 — intervention group
Group type: COMPARATOR
Intervention: Normal internal medicine treatments (Control)
Number of subjects: 52
Study 11174229 — intervention group
Group type: EXPERIMENTAL
Intervention: Report group (PRIME-MD results given to physician)
Number of subjects: 218
Study 11174229 — intervention group
Group type: COMPARATOR
Intervention: No-report group (PRIME-MD results not given to physician)
Number of subjects: 218
Study 11174229 — intervention group
Group type: EXPERIMENTAL
Intervention: Report group
Number of subjects: 218
Study 11174229 — intervention group
Group type: COMPARATOR
Intervention: No-report group
Number of subjects: 218
Study 9576535 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based retraining of attentional impairments, 12 sessions for each of the two most impaired attention functions.
Number of subjects: 22
Study 9576535 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based retraining of attentional impairments
Number of subjects: 22
Study 7931752 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician knowledge of patient expectations
Number of subjects: 360
Study 7931752 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians prescribing medications
Number of subjects: 360
Study 7931752 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician discussion of prevention or prognosis
Number of subjects: 360
Study 7931752 — intervention group
Group type: COMPARATOR
Intervention: Characteristics of care between physicians who knew and did not know patient expectations
Number of subjects: 360
Study 3652706 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant (2 ml/kg; phospholipid concentration, 100 mg/ml) administered via naso-endotracheal tube during standardized ventilatory maneuvers
Number of subjects: 8
Study 3652706 — intervention group
Group type: COMPARATOR
Intervention: Control (no surfactant)
Number of subjects: 8
Study 30972900 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention involving play-based incentives for sunscreen application
Number of subjects: 20
Study 30972900 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 20
Study 28865459 — intervention group
Group type: EXPERIMENTAL
Intervention: Indigo naturalis ointment (n = 16)
Number of subjects: 24
Study 28865459 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 8)
Number of subjects: 24
Study 25925404 — intervention group
Group type: EXPERIMENTAL
Intervention: NEMEX-TJR plus knee school educational package (KS)
Number of subjects: 45
Study 25925404 — intervention group
Group type: COMPARATOR
Intervention: KS alone
Number of subjects: 45
Study 25925404 — intervention group
Group type: EXPERIMENTAL
Intervention: NEMEX-TJR plus KS
Number of subjects: 45
Study 23868287 — intervention group
Group type: EXPERIMENTAL
Intervention: BiOSS stent
Number of subjects: 32
Study 23868287 — intervention group
Group type: COMPARATOR
Intervention: DES
Number of subjects: 32
Study 21771253 — intervention group
Group type: EXPERIMENTAL
Intervention: Angular velocity at 30° s(‐1)
Number of subjects: 11
Study 21771253 — intervention group
Group type: EXPERIMENTAL
Intervention: Angular velocity at 60° s(‐1)
Number of subjects: 11
Study 21771253 — intervention group
Group type: EXPERIMENTAL
Intervention: Angular velocity at 120° s(‐1)
Number of subjects: 11
Study 21771253 — intervention group
Group type: EXPERIMENTAL
Intervention: Angular velocity at 240° s(‐1)
Number of subjects: 11
Study 19688315 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingre Buyi Decoction (QBD) plus conventional treatment
Number of subjects: 60
Study 19688315 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 60
Study 16776607 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based (WB) training
Number of subjects: 30
Study 16776607 — intervention group
Group type: COMPARATOR
Intervention: Standardized Patient (SP) training
Number of subjects: 30
Study 14742998 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (1 g every 8 hr) from days 15 to 100 after transplantation
Number of subjects: 64
Study 14742998 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ganciclovir (6 mg/kg once per day on Monday‐Friday of each week) from days 15 to 100 after transplantation
Number of subjects: 64
Study 12900528 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg
Number of subjects: 73
Study 12900528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 12900528 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium 550 mg
Number of subjects: 73
Study 10882945 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinoic acid with Avène medical water
Number of subjects: 69
Study 10882945 — intervention group
Group type: COMPARATOR
Intervention: Retinoic acid alone
Number of subjects: 69
Study 8967861 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine-cell (EC) carcinomas
Number of subjects: 53
Study 1453403 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser vaporization
Number of subjects: 56
Study 1453403 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved epithelium
Number of subjects: 56
Study 1453403 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvolved vaginal epithelium
Number of subjects: 56
Study 1453403 — intervention group
Group type: EXPERIMENTAL
Intervention: Koilocytosis
Number of subjects: 56
Study 3893733 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine (10 mg at night)
Number of subjects: 20
Study 3893733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20